Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 26

1.

In silico-designed mutations increase variable new-antigen receptor single-domain antibodies for VEGF165 neutralization.

Millán-Gómez D, Dueñas S, Muñoz PLA, Camacho-Villegas T, Elosua C, Cabanillas-Bernal O, Escalante T, Perona A, Abia D, Drescher F, Fournier PGJ, Ramos MA, Mares RE, Paniagua-Solis J, Mata-Gonzalez T, Gonzalez-Canudas J, Hoffman RM, Licea-Navarro A, Sánchez-Campos N.

Oncotarget. 2018 Jun 15;9(46):28016-28029. doi: 10.18632/oncotarget.25549. eCollection 2018 Jun 15.

2.

Functionalized rare earth-doped nanoparticles for breast cancer nanodiagnostic using fluorescence and CT imaging.

Jain A, Fournier PGJ, Mendoza-Lavaniegos V, Sengar P, Guerra-Olvera FM, Iñiguez E, Kretzschmar TG, Hirata GA, Juárez P.

J Nanobiotechnology. 2018 Mar 22;16(1):26. doi: 10.1186/s12951-018-0359-9.

3.

Development of a functionalized UV-emitting nanocomposite for the treatment of cancer using indirect photodynamic therapy.

Sengar P, Juárez P, Verdugo-Meza A, Arellano DL, Jain A, Chauhan K, Hirata GA, Fournier PGJ.

J Nanobiotechnology. 2018 Feb 27;16(1):19. doi: 10.1186/s12951-018-0344-3.

4.

Halofuginone inhibits TGF-β/BMP signaling and in combination with zoledronic acid enhances inhibition of breast cancer bone metastasis.

Juárez P, Fournier PGJ, Mohammad KS, McKenna RC, Davis HW, Peng XH, Niewolna M, Mauviel A, Chirgwin JM, Guise TA.

Oncotarget. 2017 Sep 23;8(49):86447-86462. doi: 10.18632/oncotarget.21200. eCollection 2017 Oct 17.

5.

The vitamin D receptor is involved in the regulation of human breast cancer cell growth via a ligand-independent function in cytoplasm.

Trivedi T, Zheng Y, Fournier PGJ, Murthy S, John S, Schillo S, Dunstan CR, Mohammad KS, Zhou H, Seibel MJ, Guise TA.

Oncotarget. 2017 Apr 18;8(16):26687-26701. doi: 10.18632/oncotarget.15803.

6.

TGFβ-Mediated induction of SphK1 as a potential determinant in human MDA-MB-231 breast cancer cell bone metastasis.

Stayrook KR, Mack JK, Cerabona D, Edwards DF, Bui HH, Niewolna M, Fournier PG, Mohammad KS, Waning DL, Guise TA.

Bonekey Rep. 2015 Jul 8;4:719. doi: 10.1038/bonekey.2015.88. eCollection 2015.

7.

The TGF-β Signaling Regulator PMEPA1 Suppresses Prostate Cancer Metastases to Bone.

Fournier PG, Juárez P, Jiang G, Clines GA, Niewolna M, Kim HS, Walton HW, Peng XH, Liu Y, Mohammad KS, Wells CD, Chirgwin JM, Guise TA.

Cancer Cell. 2015 Jun 8;27(6):809-21. doi: 10.1016/j.ccell.2015.04.009. Epub 2015 May 14.

8.

FGF23 is elevated in multiple myeloma and increases heparanase expression by tumor cells.

Suvannasankha A, Tompkins DR, Edwards DF, Petyaykina KV, Crean CD, Fournier PG, Parker JM, Sandusky GE, Ichikawa S, Imel EA, Chirgwin JM.

Oncotarget. 2015 Aug 14;6(23):19647-60.

9.

Halofuginone inhibits the establishment and progression of melanoma bone metastases.

Juárez P, Mohammad KS, Yin JJ, Fournier PG, McKenna RC, Davis HW, Peng XH, Niewolna M, Javelaud D, Chirgwin JM, Mauviel A, Guise TA.

Cancer Res. 2012 Dec 1;72(23):6247-56. doi: 10.1158/0008-5472.CAN-12-1444. Epub 2012 Sep 20.

10.

TGF-beta-RI kinase inhibitor SD-208 reduces the development and progression of melanoma bone metastases.

Mohammad KS, Javelaud D, Fournier PG, Niewolna M, McKenna CR, Peng XH, Duong V, Dunn LK, Mauviel A, Guise TA.

Cancer Res. 2011 Jan 1;71(1):175-84. doi: 10.1158/0008-5472.CAN-10-2651. Epub 2010 Nov 16. Erratum in: Cancer Res. 2011 Mar 1;71(5):2023.

11.

Nitrogen-containing bisphosphonates can inhibit angiogenesis in vivo without the involvement of farnesyl pyrophosphate synthase.

Stresing V, Fournier PG, Bellahcène A, Benzaïd I, Mönkkönen H, Colombel M, Ebetino FH, Castronovo V, Clézardin P.

Bone. 2011 Feb;48(2):259-66. doi: 10.1016/j.bone.2010.09.035. Epub 2010 Oct 20.

PMID:
20920623
12.

How do bisphosphonates inhibit bone metastasis in vivo?

Fournier PG, Stresing V, Ebetino FH, Clézardin P.

Neoplasia. 2010 Jul;12(7):571-8.

13.

Hypoxia and TGF-beta drive breast cancer bone metastases through parallel signaling pathways in tumor cells and the bone microenvironment.

Dunn LK, Mohammad KS, Fournier PG, McKenna CR, Davis HW, Niewolna M, Peng XH, Chirgwin JM, Guise TA.

PLoS One. 2009 Sep 3;4(9):e6896. doi: 10.1371/journal.pone.0006896.

14.

Agents targeting prostate cancer bone metastasis.

Mohammad KS, Fournier PG, Guise TA, Chirgwin JM.

Anticancer Agents Med Chem. 2009 Dec;9(10):1079-88. Review.

PMID:
19719455
15.

Lowering bone mineral affinity of bisphosphonates as a therapeutic strategy to optimize skeletal tumor growth inhibition in vivo.

Fournier PG, Daubiné F, Lundy MW, Rogers MJ, Ebetino FH, Clézardin P.

Cancer Res. 2008 Nov 1;68(21):8945-53. doi: 10.1158/0008-5472.CAN-08-2195.

16.

Molecular biology of bone metastasis.

Kingsley LA, Fournier PG, Chirgwin JM, Guise TA.

Mol Cancer Ther. 2007 Oct;6(10):2609-17. Review.

17.

BMP7: a new bone metastases prevention?

Fournier PG, Guise TA.

Am J Pathol. 2007 Sep;171(3):739-43. Epub 2007 Aug 9. No abstract available.

18.

New insights into the role of T cells in the vicious cycle of bone metastases.

Fournier PG, Chirgwin JM, Guise TA.

Curr Opin Rheumatol. 2006 Jul;18(4):396-404. Review.

PMID:
16763461
19.

Bisphosphonates and cancer-induced bone disease: beyond their antiresorptive activity.

Clézardin P, Ebetino FH, Fournier PG.

Cancer Res. 2005 Jun 15;65(12):4971-4. Review.

20.

Contamination by nickel, copper and zinc during the handling of euro coins.

Fournier PG, Govers TR.

Contact Dermatitis. 2003 Apr;48(4):181-8.

PMID:
12786720
21.

Experimental and theoretical investigation of the spectroscopy and dynamics of multiply charged CO cations.

Lablanquie P, Delwiche J, Hubin-Franskin M, Nenner I I, Morin P, Ito K, Eland JH, Robbe J, Gandara G, Fournier J, Fournier PG.

Phys Rev A Gen Phys. 1989 Nov 15;40(10):5673-5689. No abstract available.

PMID:
9901949
22.

Double-ionization energies of CCl4 by double-charge-transfer and x-ray Auger-electron spectroscopies.

Fournier PG, Comtet G, Fournier J, Svensson S, Karlsson L, Keane MP, Naves de Brito A.

Phys Rev A Gen Phys. 1989 Jul 1;40(1):163-170. No abstract available.

PMID:
9901880
23.

Theoretical fluorescence spectrum of 3HeT+ ions formed by the beta decay of tritium in T2.

Comtet G, Fournier PG.

Phys Rev A Gen Phys. 1989 Jan 15;39(2):586-589. No abstract available.

PMID:
9901286
24.

Theoretical and experimental studies of the doubly charged ion HCl2+

Fournier PG, Mousselmal M, Peyerimhoff SD, Banichevich A, Adam MY, Morgan TJ.

Phys Rev A Gen Phys. 1987 Sep 15;36(6):2594-2602. No abstract available.

PMID:
9899165
25.

Energy distribution of H- ions produced by double capture in proton-H2 collisions.

Fournier PG, Aouchiche H, Lorent V V, Baudon J.

Phys Rev A Gen Phys. 1986 Nov;34(5):3743-3748. No abstract available.

PMID:
9897717
26.

Theoretical and experimental studies of the electronic states of the diatomic cation Cl2 2+

Fournier PG, Fournier J, Salama F, Stärk D, Peyerimhoff SD, Eland JH.

Phys Rev A Gen Phys. 1986 Sep;34(3):1657-1666. No abstract available.

PMID:
9897444

Supplemental Content

Loading ...
Support Center